CALCIGEN-S BONE VOID FILER

K013790 · Biomet Orthopedics, Inc. · MQV · Jun 11, 2002 · Orthopedic

Device Facts

• Record ID: K013790
• Device Name: CALCIGEN-S BONE VOID FILER
• Applicant: Biomet Orthopedics, Inc.
• Product Code: MQV · Orthopedic
• Decision Date: Jun 11, 2002
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 888.3045
• Device Class: Class 2

Intended Use

Calcigen™-S Bone Void Filler is indicated to fill bony voids or gaps of the skeletal system (i.e. the extremities, spine and pelvis). These defects may be surgically created osseous defects or osseous defects created from a traumatic injury to the bone. Calcigen™ -S Bone Void Filler is indicated only for bony voids or gaps that are not intrinsic to the stability of the bony structure.

Device Story

Calcigen™-S Bone Void Filler is a resorbable, radiopaque, osteoconductive, isothermic calcium sulfate-based material. Available as paste or granules. Used by surgeons to fill non-structural bony voids or gaps in the skeletal system (extremities, spine, pelvis) caused by trauma or surgery. Material resorbs and is replaced by bone during healing. No software or algorithmic components.

Clinical Evidence

No clinical data provided. Evidence consists of bench testing (material properties, dissolution rate, surface pH, biocompatibility) and animal studies demonstrating histological and mechanical equivalence to predicate.

Technological Characteristics

Calcium sulfate dihydrate-based bone void filler. Resorbable, radiopaque, osteoconductive, isothermic material. Available in paste or granule form. No software or electronic components.

Indications for Use

Indicated for filling bony voids or gaps in the skeletal system (extremities, spine, pelvis) resulting from surgery or trauma. Not for use in defects intrinsic to the stability of the bony structure.

Regulatory Classification

Identification

A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.

Special Controls

*Classification.* Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.

Predicate Devices

• Wright Plaster of Paris Pellets (OsteoSet® Pellets) (K960978, K963562, K963587)
• Wright Plaster of Paris Bone Void Filler Kit (CaSor powder) (K963587)

Submission Summary (Full Text)

{0}------------------------------------------------

K013790

UN 1 1 2002

# CORPORA ARTERS

## Summary of Safety and Effectiveness

| Applicant/Sponsor: | Biomet Orthopedics, Inc.<br>56 Bell Drive<br>P.O. Box 587<br>Warsaw, Indiana 46581-0587 |
|--------------------|-----------------------------------------------------------------------------------------|
|--------------------|-----------------------------------------------------------------------------------------|

Contact Person: Patricia Sandborn Beres Telephone: [phone] Fax: [phone]

Calcigen™-S Bone Void Filler Proprietary Name:

Calcium Sulfate Dihydrate Common Name:

Filler, Calcium Sulfate (Unclassified) Classification Name:

Legally Marketed Devices To Which Substantial Equivalence Is Claimed: Calcigen™-S Bone Void Filler is substantially equivalent to Wright Plaster of Paris Pellets (OsteoSet® Pellets) (K960978, K963562, K963587) and Wright Plaster of Paris Bone Void Filler Kit (CaSor powder)(K963587) manufactured by Wright Medical Technology, Inc., Arlington, TN.

Device Description: Calcigen™-S Bone Void Filler is a bone filler that resorbs and is replaced with bone during the healing process. The product is available in two forms, paste and granuales.

Intended Use: Calcigen™-S Bone Void Filler is indicated to fill bony voids or gaps of the skeletal system (i.e. the extremities, spine and pelvis). These defects may be surgically created osseous defects or osseous defects created from a traumatic iniury to the bone. Calcigen™ -S Bone Void Filler is indicated only for bony voids or gaps that are not intrinsic to the stability of the bony structure.

Summary of Technologies: Similar to the predicate device. Calcigen™-S Bone Void Filler is a resorbable. radiopaque, osteoconductive, isothermic calcium sulfate based material intended for identical indications.

Non-Clinical Testing: Non-clinical testing included material properties such as set time, exothermic temperature, purity, porosity and mass/volume ratio. Biocompatability testing showed the montoxic, non-mutagenic, non-hemolytic, non-cytotoxic, and non-pyrogenic. Comparative testing with the predicate device showed equivalence in terms of dissolution rate, and surface pH. Animal testing demonstrated equivalence with the predicate in an in vivo situation both histologically and mechanically.

#### Clinical Testing: none provided

All trademarks are owned by Biomet, Inc .except for the following: OsetoSet is a trademark of Wright Medical Technology, Inc.

> MAILING ADDRESS P.O. Box 587 Warsaw, IN 46581-0587

> > 1

SHIPPING ADDRESS 56 E. Bell Drive Warsaw, IN 46582

.

OFFICE 219.267.6639

Image /page/0/Picture/19 description: The image shows the word "FAX" in bold, centered above a phone number. The phone number is "219.267.8137" and is located directly below the word "FAX". The text is in a simple, sans-serif font and is likely part of a document or letterhead.

E-MAIL [e-mail]

000352

{1}------------------------------------------------

Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized image of an eagle or bird-like figure with three curved lines representing its body and wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular pattern around the bird symbol.

Public Health Service

JUN 1 1 2002

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Ms. Patricia Sandborn Beres Senior Regulatory Specialist Biomet, Inc. P.O Box 587 Warsaw, Indiana 46581-0587

Re: Re: K013790 Trade Name: Calcigen-S Bone Void Filler Regulatory Class: unclassified Product Code: MQV Dated: March 12, 2002 Received: March 14, 2002

Dear Ms. Beres:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to Mav 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. listing of devices. good manufacturing practice. labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{2}------------------------------------------------

## Page 2 - Ms. Patricia Sandborn Beres

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number [phone] or [phone] or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Mark A. Millbern

Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Devices Evaluation Center for Devices and Radiological Devices

Enclosure

{3}------------------------------------------------

510(k) Number (if known): K013790

Device Name: Calcigen™-S Bone Void Filler

### Indications For Use:

Calcigen™-S Bone Void Filler is indicated to fill bony voids or gaps of the skeletal system (i.e. the extremities, spine and pelvis). These defects may be surgically created osseous defects or osseous defects created from a traumatic injury to the bone. Calcigen™-S Bone Void Filler is indicated only for bony voids or gaps that are not intrinsic to the stability of the bony structure.

Mark A. Mikkelsen

(Division Sign-Off) Division of General, Restorative and Neurological Devices KO13790

510(k) Number -

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use
(Per 21 CFR 801.109)

OR

Over-The-Counter Use

(Optional Format 1-2-96)

000003